Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy

  • Rodríguez-García, Alba
  • Ancos-Pintado, Raquel
  • García-Vicente, Roberto
  • Ortiz-Ruiz, Alejandra
  • Arroyo, Andrés
  • Navarro, Miguel Ángel
  • Morales, María Luz
  • Guevara-Ramirez, Patricia
  • Justo, Pablo
  • López-Muñoz, Nieves
  • Sánchez-Pina, José
  • Alonso, Rafael
  • Selma, María Victoria
  • Frutos-Lisón, María Dolores
  • García-Villalba, Rocío
  • Tomás-Barberán, Francisco A.
  • Ayala Díaz, Rosa María
  • Martínez López, Joaquín
  • Linares Gómez, María
Background: Gut microbiota-derived urolithins may influence multiple myeloma (MM) disease progression and treatment. We analyzed urolithins and their associated microbiota in a retrospective cohort of 45 patients with active MM or premalignant disease using mass spectrometry and 16S rRNA gene sequencing. Results: Patients with detectable levels of urolithin in serum and stool and a higher abundance of urolithin-related microbiota had a better outcome. Analysis of the effects of urolithin A (UroA) treatment ex vivo, in vitro, and in vivo revealed that UroA is cytotoxic against MM cell lines and modulates the cell cycle and mitochondrial activity. Notably, UroA inhibits the proliferation of primary MM cells in vitro and in a xenograft mouse model, improving overall survival. Finally, combination therapy with UroA and bortezomib has a synergistic effect in vitro, even in the presence of bortezomib resistance, and modulates signaling pathways involved in MM development. Conclusions: UroA might be a potential therapeutic agent to halt MM disease progression or to overcome resistance when used in combination.
Docta Complutense
Publicación Artículo científico (JournalArticle)

The Potential of the Gut Microbiota and Butyrate to Enhance CAR-T Cell Therapy in Non-Hodgkin Lymphoma

  • Garcia-Vicente, Roberto
  • Rodríguez-García, Alba
  • Ancos-Pintado, Raquel
  • Arroyo, Andrés
  • Ortega-Hernández, Adriana
  • Bragado-García, Irene
  • Castellano, Eva
  • Ortiz-Ruiz, Alejandra
  • Navarro-Aguadero, Miguel Ángel
  • Modrego, Javier
  • Leivas, Alejandra
  • García-Villalba, Rocío
  • Tomás-Barberán, Francisco A
  • Sánchez-Pina, Jose María
  • Alonso, Rafael
  • Cedena Romero, M. Teresa
  • Carpio, Cecilia
  • Barba, Pere
  • Carbonell, Diego
  • Kwon, Mi
  • Bastos-Oreiro, Mariana
  • Martín García-Sancho, Alejandro
  • Jiménez-Ubieto, Ana
  • Valeri, Antonio
  • Gómez-Garre, Dulcenombre
  • Linares Gómez, María
  • Hernández Sánchez, María
  • Martínez López, Joaquín
Purpose: The microbiota is recognized as an important contributor to the efficacy of immunotherapies. The aim of this study is to analyse the role of gut microbiota, and related metabolites, in the response of CAR-T cells for non-Hodgkin lymphoma (NHL). Experimental design: Stool, serum, and clinical data were collected from 84 NHL patients from four hospitals before CD19 CAR-T treatment. The microbiota was characterized through 16S rRNA gene sequencing and serum short-chain fatty acids (SCFAs) were measured using mass spectroscopy. CAR-T cells were exposed to butyrate; their in vitro cytotoxicity was determined, and molecular mechanisms were characterized by flow cytometry and RNA-seq, then assessed in an in vivo model. Results: Since we confirmed the negative impact of antibiotics on the response, we delved into the mechanisms involved. We showed that they reduce microbiota diversity, and that their composition correlates with the response. We identified SCFA-producing bacterial groups including Prevotella, Ruminococcus, or Butyricicoccus as having a relatively higher abundance in the microbiota of patients who responded to CAR-T. Analysis of butyrate levels revealed a positive correlation with survival, potentially representing a novel biomarker of response. Finally, we found that stimulation of CAR-T cells with butyrate induced phenotypic and transcriptomic changes associated with enhanced antitumor efficacy. Conclusions: Our results support the relationship between microbiota and CAR-T therapy major outcomes. Analysis of microbiota led to the identification of SCFAs, especially butyrate as a prognostic factor, and also provides the basis for considering them as chemical modifiers of CAR-T cells to improve their efficacy.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma

  • Rodríguez-García, Alba
  • Arroyo, Andrés
  • García-Vicente, Roberto
  • Morales, María Luz
  • Gómez-Gordo, Rubén
  • Justo, Pablo
  • Cuéllar, Clara
  • Sánchez-Pina, José María
  • López, Nieves
  • Alonso, Rafael
  • Puig, Noemi
  • Mateos, Maria Victoria
  • Ayala Bueno, Rosa
  • Gómez-Garre, Dulcenombre
  • Martínez-López, Joaquín
  • Linares, María
[Purpose]: The gut microbiota plays important roles in health and disease. We questioned whether the gut microbiota and related metabolites are altered in monoclonal gammopathies and evaluated their potential role in multiple myeloma and its response to treatment., [Experimental Design]: We used 16S rRNA sequencing to characterize and compare the gut microbiota of patients with monoclonal gammopathy of undetermined significance (n = 11), smoldering multiple myeloma (n = 9), newly diagnosed multiple myeloma (n = 11), relapsed/refractory multiple myeloma (n = 6), or with complete remission (n = 9). Short-chain fatty acids (SCFA) were quantified in serum and tested in cell lines. Relevant metabolites were validated in a second cohort of 62 patients., [Results]: Significant differences in alpha- and beta diversity were present across the groups and both were lower in patients with relapse/refractory disease and higher in patients with complete remission after treatment. Differences were found in the abundance of several microbiota taxa across disease progression and in response to treatment. Bacteria involved in SCFA production, including Prevotella, Blautia, Weissella, and Agathobacter, were more represented in the premalignant or complete remission samples, and patients with higher levels of Agathobacter showed better overall survival. Serum levels of butyrate and propionate decreased across disease progression and butyrate was positively associated with a better response. Both metabolites had antiproliferative effects in multiple myeloma cell lines., [Conclusions]: We demonstrate that SCFAs metabolites and the gut microbiota associated with their production might have beneficial effects in disease evolution and response to treatment, underscoring its therapeutic potential and value as a predictor., This work was supported by grant PID2021-123056OA-I00 funded by MCIN/AEI/10.13039/501100011033 and ERDF A way of making Europe, the Instituto de Investigación Hospital 12 de Octubre (i+12), CIBERONC, AECC (Accelerator Award and Ideas Semilla, IDEAS20014LINA), and the CRIS foundation. A. Rodríguez-García is the recipient of a grant from the Sociedad Española de Hematología y Hemoterapia, and R. Garcia-Vicente holds a predoctoral fellowship (FPU) grant from the Ministry of Science, Innovation and Universities of Spain (FPU19/04933)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy

  • Rodríguez-García, Alba
  • Ancos-Pintado, Raquel
  • García-Vicente, Roberto
  • Ortiz-Ruiz, Alejandra
  • Arroyo, Andrés
  • Navarro, Miguel Ángel
  • Morales, María Luz
  • Guevara-Ramirez, Patricia
  • Justo, Pablo
  • López-Muñoz, Nieves
  • Sánchez-Pina, José
  • Alonso, Rafael
  • Selma, María Victoria
  • Frutos-Lisón, María Dolores
  • García-Villalba, Rocío
  • Tomás Barberán, Francisco
  • Ayala, Rosa
  • Martínez-López, Joaquín
  • Millán-Linares, María del Carmen
Gut microbiota-derived urolithins may influence multiple myeloma (MM) disease progression and treatment. We analyzed urolithins and their associated microbiota in a retrospective cohort of 45 patients with active MM or premalignant disease using mass spectrometry and 16S rRNA gene sequencing., This work was supported by Grant PID2021-123056OA-I00 funded by MCIN/AEI/10.13039/501100011033 and ERDF A way of making Europe, the Instituto de Investigación Hospital 12 de Octubre (imas12), CIBERONC, AECC (Accelerator Award and Ideas Semilla, IDEAS20014LINA), and the CRIS foundation. A. R. G. and R. G. V. were the recipient of a grant from the Sociedad Española de Hematología y Hemoterapia; R. G. V. holded a predoctoral fellowship (FPU) grant from the Ministry of Science, Innovation and Universities of Spain (FPU19/04933); and R. A. P. holds a grant from ISCIII/CDTI (PMPTA22/00088), Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

When Teaching and Learning Microbiology Engage Societal Needs

  • Valderrama Conde, María José
  • Nebreda, Etna
  • López Ejeda, Noemí
  • Linares Gómez, María
This article explores the integration of community-based learning into microbiology education, using as an example the Service-Learning (S-L) programme ‘Movies in company for preventing diseases’ implemented at the Complutense University of Madrid. The programme exemplifies how academic knowledge can be effectively applied to address societal issues focused on disadvantaged populations. The issue describes the basis and quality criteria for designing a S-L in clinical microbiology: real needs identification, student's curricular connection, social engagement and learning link, assessment of active participation of students, commitment outside university campus and recognition and assessment. The impact on university participants and community partners and the contribution to university social responsibility is also presented. The S-L programme fosters social engagement in all participants, both students and university tutors, and positively impacts community underserved members by providing crucial health information and support. The success of this programme highlights its potential as a model for integrating academic learning in microbiology with societal needs and emphasises the role of universities in addressing global challenges.